

**Table S4.** Patient and tumor characteristics of sporadic patients in relation to molecular subtypes

<b>Sporadic tumors</b>	<b>Basal (n = 10)</b>	<b>HER2 (n = 14)</b>	<b>LumA (n = 55)</b>	<b>LumB (n = 48)</b>	<b>Normal (n = 1)</b>
<b>Estrogen receptor</b>					
ER+	0	3	55	48	1
ER-	10	11	0	0	0
<b>Progesterone receptor</b>					
PR+	0	1	47	30	1
PR-	10	13	8	18	0
<b>HER2 status</b>					
HER2+	1	13	4	3	0
HER2-	9	1	51	45	1
<b>Histologic grade</b>					
Grade 1	1	0	27	4	0
Grade 2	0	4	19	25	0
Grade 3	8	9	0	11	1
NA	1	1	9	8	0
<b>Tumor type</b>					
Invasive ductal carcinoma	10	13	42	39	1
Invasive lobular carcinoma	0	0	9	3	0
Mucinous carcinoma	0	0	1	1	0
Medullary carcinoma	0	0	0	1	0
Tubular carcinoma	0	0	2	1	0
Metaplastic carcinoma	0	0	0	0	0
Other	0	0	0	2	0
NA	0	1	1	1	0
<b>Age</b>					
< 50 years	0	3	8	9	1
≥ 50 years	10	11	47	39	0
<b>Menopause status</b>					
Premenopausal	1	3	12	13	1
Perimenopausal	2	2	4	7	0
Postmenopausal	6	8	37	27	0
Other	0	0	2	0	0
NA	1	1	0	1	0